ALISON GRACE CHANG MD NPI 1205253465

NPI Details

Alison Grace Chang, MD is a hematology and oncology internal medicine in Palo Alto, CA with 12 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Alison Grace Chang, MD NPI is 1205253465. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

795 EL CAMINO REAL
PALO ALTO, CA
ZIP 94301-302
Phone: (650) 853-2905

The NPI 1205253465 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, vedolizumab, 1 mg (HCPCS:J3380)
• Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1459)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Bcg live intravesical instillation, 1 mg (HCPCS:J9030)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Instillation of anti-cancer drug into bladder (HCPCS:51720)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Drawing of blood for a medical problem (HCPCS:99195)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Unclassified drugs (HCPCS:J3490)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)

The enumeration date for this NPI number is 3/26/2014 and was last updated on 8/3/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: